Monograph of Ferrous Sulfate

Introduction

Definition and Overview

Ferrous sulfate (FeSO₄·7H₂O, commonly referred to as FeSO₄·7H₂O) is an inorganic iron salt frequently utilized as an oral iron supplement. It delivers elemental iron in a readily absorbable form and is widely employed to correct iron deficiency states. The compound is available in various dosage strengths, typically ranging from 20 mg to 325 mg of elemental iron per tablet or capsule.

Historical Background

Early recognition of iron’s therapeutic role emerged in the late nineteenth century, when iron salts were first applied to treat anemia. Ferrous sulfate gained prominence during the twentieth century due to its favorable bioavailability and cost-effectiveness compared with other iron preparations. Its formulation has evolved, with newer enteric-coated or sustained-release variants introduced to mitigate gastrointestinal side effects.

Importance in Pharmacology and Medicine

Iron is a critical component of hemoglobin, myoglobin, and numerous enzymatic systems. Deficiency precipitates microcytic, hypochromic anemia, growth retardation, and impaired cognitive development. Adequate iron replacement is pivotal in obstetrics, pediatrics, oncology, and chronic disease management. Ferrous sulfate, as the most common oral iron formulation, serves as a cornerstone in therapeutic protocols worldwide.

Learning Objectives

• Describe the chemical structure and physicochemical properties of ferrous sulfate.
• Explain the mechanisms governing intestinal absorption and systemic disposition.
• Identify factors influencing bioavailability and therapeutic efficacy.
• Apply dosing principles to diverse patient populations and clinical scenarios.
• Recognize and manage adverse effects and drug–drug interactions associated with ferrous sulfate therapy.

Fundamental Principles

Core Concepts and Definitions

Ferrous sulfate is defined by its iron oxidation state (+2), sulfate counterion (SO₄²⁻), and associated waters of crystallization. The elemental iron content (Fe) is approximately 20% by mass in the monohydrate form, increasing to 22% in the heptahydrate. The compound is classified as an inorganic salt, acidic in aqueous solution, and exhibits limited water solubility at neutral pH.

Theoretical Foundations of Iron Metabolism

Iron homeostasis is regulated by dietary absorption, recycling from senescent erythrocytes, and storage in ferritin and hemosiderin. Hepcidin, a liver-derived peptide hormone, serves as the principal negative regulator of intestinal absorption and macrophage release. The transport of ferrous iron across the apical membrane of enterocytes is mediated by divalent metal transporter 1 (DMT1), whereas basolateral export is facilitated by ferroportin. Subsequent oxidation to ferric iron (Fe³⁺) and binding to transferrin in the circulation completes the absorption process.

Key Terminology

• Elemental Iron: The actual iron content in a supplement, expressed in milligrams.
• Bioavailability: The proportion of administered iron that is absorbed and becomes available for physiological functions.
• Hepcidin: A peptide hormone that modulates iron egress from enterocytes and macrophages.
• DMT1: A transmembrane protein responsible for transporting Fe²⁺ into enterocytes.
• Ferroportin: The sole known iron exporter from enterocytes and macrophages into plasma.
• Transferrin: A glycoprotein that transports iron in the bloodstream.

Detailed Explanation

Chemical and Physical Properties

In aqueous solution, ferrous sulfate dissociates into Fe²⁺ and SO₄²⁻ ions. The stability constant of the Fe²⁺·SO₄²⁻ complex is high, which facilitates rapid dissolution in the gastric milieu. The acidic pH (≈1.5–3.5) of the stomach promotes the formation of soluble Fe²⁺, whereas higher pH in the small intestine reduces solubility, limiting absorption. The presence of ascorbic acid or other reducing agents can enhance solubility and absorption by maintaining iron in the +2 oxidation state.

Mechanisms of Intestinal Absorption

Ferrous sulfate absorption follows a saturable, carrier-mediated process. The key steps include: (1) dissolution of the salt in gastric acid; (2) reduction of Fe³⁺ to Fe²⁺ by duodenal ferrireductases; (3) transport of Fe²⁺ into enterocytes via DMT1; (4) oxidation to Fe³⁺ within the basolateral membrane; (5) export into circulation by ferroportin; and (6) complexation with transferrin. The efficiency of absorption is influenced by dietary factors, such as calcium, phytates, polyphenols, and oxalates, which can inhibit iron uptake, and enhancers like vitamin C.

Pharmacokinetic Relationships

The pharmacokinetics of oral ferrous sulfate can be approximated by a two-compartment model, with absorption phase characterized by a first-order rate constant (k_a) and elimination phase by k_el. The concentration-time profile may be expressed as:
C(t) = (F × Dose × k_a ÷ (V_d (k_a − k_el))) × (e^−k_elt − e^−k_at),
where F represents bioavailability, V_d the apparent volume of distribution, and t the time post-dose. Clearance (Cl) is defined as Cl = k_el × V_d, and the area under the concentration-time curve (AUC) equals Dose ÷ Cl. These equations highlight the inverse relationship between clearance and AUC, underscoring the importance of dosing adjustments in hepatic impairment.

Factors Affecting Bioavailability

• pH: Gastric acidity facilitates solubilization; proton pump inhibitor therapy can decrease absorption.
• Dietary Inhibitors: Calcium, iron from other sources, phytates, tannins, and oxalates competitively inhibit DMT1.
• Enhancers: Ascorbic acid, citric acid, and other reducing agents increase solubility and absorption.
• Formulation: Enteric-coated or sustained-release forms may reduce peak plasma concentrations, potentially mitigating gastrointestinal irritation but also lowering bioavailability.
• Genetic Variants: Polymorphisms in DMT1 or ferroportin may alter absorption efficiency.

Clinical Significance

Relevance to Drug Therapy

Ferrous sulfate occupies a central role in treating iron deficiency anemia across multiple populations: pregnant women, infants, adolescents, patients with chronic kidney disease, inflammatory bowel disease, and cancer cachexia. Its high elemental iron concentration allows for lower tablet counts, simplifying adherence. However, its propensity for gastrointestinal adverse events necessitates careful dosing strategies and patient counseling.

Practical Applications

Therapeutic regimens typically involve 60–325 mg of elemental iron per day, divided into 2–3 doses to maximize absorption while minimizing irritation. Dose adjustments are guided by hemoglobin targets, ferritin levels, and tolerability. In situations of rapid anemia correction, such as preoperative optimization, higher daily doses (up to 400 mg elemental iron) may be justified under close monitoring.

Clinical Examples

1. A 28‑year‑old primigravida with hemoglobin of 9.5 g/dL and serum ferritin of 8 ng/mL is prescribed 325 mg ferrous sulfate daily. After 8 weeks, hemoglobin rises to 12.8 g/dL, and ferritin increases to 90 ng/mL. Adverse events include mild nausea and mild constipation, managed with a dietary recommendation for high‑fiber foods.

2. A 54‑year‑old male undergoing chemotherapy presents with anemia (hemoglobin 8.0 g/dL). A maintenance dose of 200 mg elemental iron daily is initiated, and ferritin is monitored monthly. Over three months, hemoglobin improves to 10.2 g/dL, with tolerable gastrointestinal side effects.

Clinical Applications/Examples

Case Scenario 1: Pediatric Iron Deficiency

A 6‑year‑old boy exhibits microcytic, hypochromic anemia with hemoglobin 9.2 g/dL and ferritin 12 ng/mL. A pediatric dosing regimen of 20 mg elemental iron twice daily is prescribed. Follow‑up at 6 weeks reveals hemoglobin 11.5 g/dL and ferritin 45 ng/mL. The child tolerates therapy with occasional mild abdominal discomfort, which resolves with meal timing adjustments.

Case Scenario 2: Chronic Kidney Disease

A 62‑year‑old female with stage 4 chronic kidney disease (estimated glomerular filtration rate 25 mL/min/1.73 m²) has hemoglobin 10.5 g/dL. Oral ferrous sulfate 200 mg elemental iron daily is initiated, with concurrent vitamin D supplementation to enhance erythropoiesis. After 12 weeks, hemoglobin rises to 11.8 g/dL without significant iron overload, as indicated by ferritin 95 ng/mL.

Problem‑Solving Approach to Adverse Effects

• Identify the symptom: nausea, dyspepsia, or constipation.
• Adjust dosing schedule: split the total daily dose into 2–3 administrations separated by at least 3 hours.
• Implement dietary modifications: take tablets with small amounts of food to buffer gastric irritation.
• Consider alternative formulations: enteric-coated or sustained-release preparations for patients with severe gastrointestinal intolerance.
• Reassess after 2–4 weeks; if intolerance persists, transition to a different iron formulation (e.g., ferrous fumarate or iron polysaccharide).

Drug–Drug Interactions

Ferrous sulfate may interfere with absorption of several medications, including tetracyclines, fluoroquinolones, levothyroxine, and bisphosphonates. Conversely, proton pump inhibitors decrease absorption. The general recommendation is to administer ferrous sulfate at least 2 hours before or after these agents. Monitoring for therapeutic efficacy and potential drug–drug interactions is essential, especially in polypharmacy contexts.

Summary/Key Points

• Ferrous sulfate delivers elemental iron in a form with high bioavailability, contingent upon gastrointestinal pH and dietary factors.
• Intestinal absorption is mediated by DMT1 and ferroportin, with regulation by hepcidin.
• Pharmacokinetic parameters (k_a, k_el, Cl, AUC) guide dosing and therapeutic monitoring.
• Clinical dosing ranges from 60 to 325 mg elemental iron per day, tailored to disease state, severity of anemia, and patient tolerability.
• Adverse effects are predominantly gastrointestinal; mitigation strategies include dose splitting, dietary adjustments, and formulation changes.
• Drug–drug interactions are significant; timing of administration relative to other medications must be considered.
• Monitoring of hemoglobin, ferritin, and transferrin saturation is recommended to assess response and avoid iron overload.
• Ferrous sulfate remains a cornerstone of iron replacement therapy across diverse patient populations.

References

1. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
2. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
5. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
6. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
7. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
8. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.